WO2004112783A1 - Utilisation iv - Google Patents

Utilisation iv Download PDF

Info

Publication number
WO2004112783A1
WO2004112783A1 PCT/SE2004/000959 SE2004000959W WO2004112783A1 WO 2004112783 A1 WO2004112783 A1 WO 2004112783A1 SE 2004000959 W SE2004000959 W SE 2004000959W WO 2004112783 A1 WO2004112783 A1 WO 2004112783A1
Authority
WO
WIPO (PCT)
Prior art keywords
thiazol
chloro
benzenesulfonamide
dichloro
phenyl
Prior art date
Application number
PCT/SE2004/000959
Other languages
English (en)
Inventor
Cecilia Nilsson
Catrine Dreifeldt
Original Assignee
Biovitrum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovitrum Ab filed Critical Biovitrum Ab
Publication of WO2004112783A1 publication Critical patent/WO2004112783A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Definitions

  • the present invention relates to the use of chemical compounds for wound healing, said compounds acting on the human 11- ⁇ -hydroxysteroid dehydrogenase type 1 enzyme (ll ⁇ HSDl).
  • Cortisol performs a broad range of metabolic functions and other functions.
  • the multitude of glucocorticoid action is exemplified in patients with prolonged increase in plasma glucocorticoids, so called "Cushing's syndrome".
  • Patients with Gushing' s syndrome have prolonged increase in plasma glucocorticoids and exhibit impaired glucose tolerance, type 2 diabetes, central obesity, and osteoporosis. These patients also have impaired wound healing and brittle skin ( 1 ).
  • Glucocorticoids have been shown to increase risk of infection and delay healing of open wounds (2). Patients treated with glucocorticoids have 2-5-fold increased risk of complications when undergoing surgery (3).
  • the European patent application No. EP 0902288 discloses a method for diagnosing the status of wound healing in a patient, comprising detecting cortisol levels in said wound.
  • the authors suggest that elevated levels of cortisol in wound fluid, relative to normal plasma levels in healthy individuals, correlates with large, non-healing wounds (4).
  • the 1 l ⁇ -HSD catalyzes the conversion of cortisol to cortisone, and vice versa.
  • the parallel function of 1 l ⁇ -HSD in rodents is the interconversion of corticosterone and 11-dehydrocorticosterone (5).
  • Wound healing consists of serial events including inflammation, fibroblast proliferation, secretion of ground substances, collagen production, angiogenesis, wound contraction and epithelialization. It can be divided in three phases; inflammatory, proliferative and remodeling phase (reviewed in (2)).
  • glucocorticoids In surgical patients, treatment with glucocorticoids increases risk of wound infection and delay healing of open wounds. It has been shown in animal models that restraint stress slows down cutaneous wound healing and increases susceptibility to bacterial infection during wound healing. These effects were reversed by treatment with the glucocorticoid receptor antagonist RU486 (14, 15). Glucocorticoids produce these effects by suppressing inflammation, decrease wound strength, inhibit wound contracture and delay epithelialization (2). Glucocorticoids influence wound healing by interfering with production or action of cytokines and growth factors like IGF, TGF- ⁇ , EGF, KGF and PDGF (16-19). It has also been shown that glucocorticoids decrease collagen synthesis in rat and mouse skin in vivo and in rat and human fibroblasts (20).
  • WO 01/90092 discloses compounds of the formula (I) as defined hereinafter, which compounds inhibit the human 1 l ⁇ -HSD 1, and may be useful for treating disorders such as diabetes, obesity, glaucoma, osteoporosis, cognitive disorders and immune disorders.
  • Other 11 ⁇ -HSDl inhibitors are disclosed in e.g. WO 01/90090; WO 01/90091 ; WO 01/90093; WO 01/90094; WO 03/044000; WO 03/044009; WO 03/043999; and Swedish patent application No. SE 0301504-7, filed on May 21, 2003.
  • WO 02/072084 relates to glycyrrhetinic acid derivatives, progesterone and progesterone derivatives as ll ⁇ -HSDl inhibitors for wound healing.
  • the use of the 1 l ⁇ -HSD 1 inhibitors according to the present invention for wound healing has not previously been disclosed.
  • this invention provides a method for promoting wound healing, said method comprising administering to a mammal, including man, in need of wound healing an effective amount of an inhibitor of 1 l ⁇ -hydroxysteroid dehydrogenase type 1, wherein the inhibitor of 11 ⁇ - hydroxysteroid dehydrogenase type 1 is a compound of the formula (I):
  • T is an aryl ring or heteroaryl ring, optionally independently substituted by [R] n , wherein n is an integer 0-5, and R is hydrogen, halogen, C ⁇ -6-alkyl, and aryl;
  • A is selected from an aryl ring or heteroaryl ring, which can further be optionally substituted in one or more positions independently of each other by hydrogen, C h alky!, halogenated C 1-6 -alkyL halogen, C 1-6 -alkoxy, nitro, C ⁇ -6 -alkoxycarbonyl, C 1-6 - alkylsulfonyl, acetylamino or aryloxy, wherein the aryloxy can further be optionally substituted in one or more positions independently of each other by hydrogen and halogen; and
  • B is selected from hydrogen and C 1-6 -alkoxycarbonyl or is linked to A to give a 6- membered aromatic or non-aromatic ring; pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers, N-oxides and prodrug forms thereof.
  • T is selected from thienyl substituted with one or more of bromo, chloro; and phenyl optionally substituted with one or more of chloro, methyl, propyl, phenyl, bromo, fluoro;
  • A is selected from l-benzothien-3-yl, 3-(2,5-dimethylfuryl), pyridinyl; thienyl optionally substituted with one or more of chloro, methylsulfonyl; phenyl optionally substituted with one or more of ethoxycarbonyl, nitro, fluoro, methyl, methoxy, acetylamino, chloro, 4-chlorophenoxy, trifluoromethyl;
  • B is selected from hydrogen, carbethoxy or is linked to A to give a 6-membered aromatic or non-aromatic ring.
  • the said method is a method for the treatment or prophylaxis of a medical condition involving delayed or impaired wound healing.
  • diabetes examples of such medical conditions are diabetes, and conditions caused by treatment with steroids, in particular glucocorticoids.
  • the method according to the invention is also intended for the promotion of wound healing in chronic wounds, such as diabetic ulcers, venous ulcers or pressure ulcers.
  • the compounds referred to above may also be used in the manufacture of a medicament for promoting wound healing, e.g. for the treatment or prophylaxis of a medical condition involving delayed or impaired wound healing.
  • a medical condition involving delayed or impaired wound healing.
  • medical conditions are diabetes, and conditions caused by treatment with steroids, in particular glucocorticoids.
  • the compounds referred to above may also be used for the promotion of wound healing in chronic wounds, such as diabetic ulcers, venous ulcers or pressure ulcers.
  • aryl in the present description is intended to include aromatic rings (monocyclic or bicyclic) having from 6 to 10 ring carbon atoms, such as phenyl (Ph) and naphthyl, which optionally may be substituted by C 1-6 -alkyl.
  • substituted aryl groups are benzyl, and 2-methylphenyl.
  • heteroaryl means in the present description a monocyclic, bi- or tricyclic aromatic ring system (only one ring need to be aromatic) having from 5 to 14, preferably 5 to 10 ring atoms such as 5, 6, 7, 8, 9 or 10 ring atoms (mono- or bicyclic), in which one or more of the ring atoms are other than carbon, such as nitrogen, sulfur, oxygen and selenium.
  • heteroaryl rings examples include pyrrole, imidazole, thiophene, furan, thiazole, isothiazole, thiadiazole, oxazole, isoxazole, oxadiazole, pyridine, pyrazine, pyrimidine, pyridazine, pyrazole, triazole, tetrazole, chroman, isochroman, quinoline, quinoxaline, isoquinoline, phthalazine, cinnoline, quinazoline, indole, isoindole, indoline, isoindoline, benzothiophene, benzofuran, isobenzofuran, benzoxazole, 2,1,3-benzoxadiazole, benzothiazole, 2,1,3-benzothiazole, 2,1,3- benzoselenadiazole, benzimidazole, indazole, benzodioxane, indan
  • Examples of monocyclic heteroaryl rings are pyrrole, imidazole, thiophene, furan, thiazole, isothiazole, thiadiazole, oxazole, isoxazole, oxadiazole, pyridine, pyrazme, pyrimidine, pyridazine, pyrazole, triazole, and tetrazole.
  • heterocyclic in the present description is intended to include unsaturated as well as partially and fully saturated mono-, bi- and tricyclic rings having from 4 to 14, preferably 4 to 10 ring atoms, such as, for example, the heteroaryl groups mentioned above as well as the corresponding partially saturated or fully saturated heterocyclic rings.
  • exemplary saturated heterocyclic rings are azetidine, pyrrolidine, piperidine, piperazine, morpholine, thiomorpholine and 1,4-oxazepane.
  • C ⁇ _6 ⁇ alkyl in the compound of formula (I) according to the present application is preferably C ⁇ _4-alkyl.
  • Exemplary alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, pentyl, isopentyl, hexyl, and isohexyl.
  • C 1-6 -alkyl For parts of the range "C 1-6 -alkyl" all subgroups thereof are contemplated such as d-s-alkyl, C 1-4 -alkyl, C 2-6 -alkyl, C 2- 5-alkyl, C 2-4 -alkyl, C 2-3 - alkyl, C 3-6 -alkyl, C -5-alkyl, etc.
  • Cj.g-alkoxy, in the compound of formula (I) according to the present application may be straight or branched, is preferably C ⁇ _4-alkoxy.
  • alkoxy groups include methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butoxy, tert-butoxy, pentyloxy, isopentyloxy, hexyloxy, and isohexyloxy.
  • C 1-6 -alkoxy all subgroups thereof are contemplated such as Cj.s-alkoxy, C 1- -alkoxy, C 2-6 -alkoxy, C 2 - 5 - alkoxy, C 2-4 -alkoxy, C 2-3 -alkoxy, C -6 -alkoxy, C 4-5 -alkoxy, etc.
  • Ci-g-acyl, in the compound of formula (I) according to the present application may be saturated or unsaturated and is preferably C ⁇ _4-acyl.
  • exemplary acyl groups include foraiyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, butenoyl (e.g. 3- butenoyl), hexenoyl (e.g. 5-hexenoyl).
  • C 1-6 -acyl For parts of the range "C 1-6 -acyl" all subgroups thereof are contemplated such as C 1-5 -acyl, C 1-4 -acyl, C 2-6 -acyl, C 2-5 -acyl, C 2-4 -acyl, C 2- 3 -acyl, C 3-6 -acyl, C 4-5 -acyl, etc.
  • C 2-6 -alkenyl in the compound of formula (I) according to the present application is preferably C 2-4 -alkenyl.
  • Exemplary alkenyl groups include vinyl, 1-pro ⁇ enyl, 2-propenyl, isopropenyl, 1-butenyl, 2-butenyl, 1- pentenyl, 2-pentenyl, 1-hexenyl, and 2-hexenyl.
  • C 2- 6-alkenyl all subgroups thereof are contemplated such as C -5 -alkenyl, C 2-4 -alkenyl, C 2-3 -alkenyl, C 3- 6 -alkenyl, C - 5 -alkenyl, etc.
  • halogen in the present description is intended to include fluorine, chlorine, bromine and iodine.
  • mono- or di-substituted is meant in the present description that the functionalities in question may be substituted with independently H, C ⁇ -6 -acyl, C 1-6 - alkenyl, C 1-6 -(cyclo)alkyl, aryl, pyridylmethyl, or heterocyclic rings e.g. azetidine, pyrrolidine, piperidine, piperazine, morpholine and thiomorpholine, which heterocyclic rings optionally may be substituted with C 1-6 -alkyl.
  • optionally mono- or disubstituted is meant in the present description that the functionalities in question may also be substituted with independently hydrogen.
  • stable referes to compounds which possess stability sufficient to allow manufacture and which maintains the integrity of the compound for a sufficient period of time to be useful for the purposes detailed herein (e.g., therapeutic administration to a subject for the treatment of disease, 11- ⁇ -HSDl inhibition, 11 - ⁇ -HSDl -mediated disease).
  • prodrug forms in the present description means a pharmacologically acceptable derivative, such as an ester or an amide, which derivative is biotransformed in the body to form the active drug (see Goodman and Gil an's, The Pharmacological basis of Therapeutics, 8 th ed., McGraw-Hill, Int. Ed. 1992, "Biotransformation of Drugs, p. 13-15).
  • “Pharmaceutically acceptable” means in the present description being useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable and includes being useful for veterinary use as well as human pharmaceutical use.
  • “Pharmaceutically acceptable salts” mean in the present description salts which are pharmaceutically acceptable, as defined above, and which possess the desired pharmacological activity.
  • Such salts include acid addition salts formed with organic and inorganic acids, such as hydrogen chloride, hydrogen bromide, hydrogen iodide, sulfuric acid, phosphoric acid, acetic acid, glycolic acid, aleic acid, malonic acid, oxalic acid, methanesulfonic acid, trifluoroacetic acid, fumaric acid, succinic acid, tartaric acid, citric acid, benzoic acid, ascorbic acid and the like.
  • Base addition salts may be formed with organic and inorganic bases, such as sodium, ammonia, potassium, calcium, ethanolamine, diethanolamine, N-methylglucamine, choline and the like.
  • the compounds of formula (I) can be prepared according to the methods described in WO 01/90092.
  • the compounds of formula (I) can preferably be topically administered.
  • the compounds could also be administered by other routes, for instance orally, intraperitoneally, intraarticularly, intracranially, intradermally, intramuscularly, intraocularly, intrathecally, intravenously, subcutaneously.
  • Diabetic KKA y mice underwent surgery during anesthesia whereby a catheter was inserted in the jugularis vein. Oral treatment twice daily (200 mg/kg/day) with the ll ⁇ - HSDl inhibitor BVT.2733 (disclosed as Example 172A in WO 01/90090), or vehicle started 4-6 days later and continued for 3.5 days.
  • ll ⁇ -HSDl inhibitors e.g. BVT.2733
  • BVT.2733 ll ⁇ -HSDl inhibitors
  • Hutchinson TC Swaniker HP. Wound diagnosis by quantitating cortisol in wound fluids.
  • Beer HD Fassler R, Werner S. Glucocorticoid-regulated gene expression during cutaneous wound repair. Vitam Horm 2000;59:217-39.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne une méthode permettant de favoriser la guérison de blessures et consistant à administrer à un mammifère, notamment l'être humain, nécessitant un tel traitement, une quantité efficace d'un inhibiteur de la 11-ß-hydroxystéroïde déshydrogénase de type 1 (11ß-HSD1), ledit inhibiteur de la 11ß-HSD1 étant de formule (I), dans laquelle T, A et B sont définis dans la description. Ces composés peuvent également être utilisés dans la fabrication d'un médicament favorisant la guérison de blessures.
PCT/SE2004/000959 2003-06-25 2004-06-16 Utilisation iv WO2004112783A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0301885-0 2003-06-25
SE0301885A SE0301885D0 (sv) 2003-06-25 2003-06-25 New use IV

Publications (1)

Publication Number Publication Date
WO2004112783A1 true WO2004112783A1 (fr) 2004-12-29

Family

ID=27656620

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2004/000959 WO2004112783A1 (fr) 2003-06-25 2004-06-16 Utilisation iv

Country Status (2)

Country Link
SE (1) SE0301885D0 (fr)
WO (1) WO2004112783A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007025892A1 (fr) 2005-08-31 2007-03-08 F. Hoffmann-La Roche Ag Inhibiteur de la 11-bêta-hydroxystéroïde déhydrogénase-1 des diabètes de type 2-1
EP1791822A1 (fr) * 2004-08-05 2007-06-06 F.Hoffmann-La Roche Ag Aminothiazoles substitués n-acyle-2-
US7253196B2 (en) 2004-05-24 2007-08-07 Amgen, Inc. Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1
US7759339B2 (en) 2005-03-31 2010-07-20 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
US8541592B2 (en) 2005-11-22 2013-09-24 Amgen Inc. Inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1
US8686011B2 (en) 2004-05-24 2014-04-01 Amgen Inc. Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1
EP3235813A1 (fr) 2016-04-19 2017-10-25 Cidqo 2012, S.L. Dérivés aza-tétra-cycliques

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1240545A (en) * 1967-07-17 1971-07-28 Research Corp Silver-containing therapeutic agents
WO1996031492A1 (fr) * 1995-04-04 1996-10-10 Texas Biotechnology Corporation Thienyl-, furyl-, pyrrolyl- et biphenyl sulfonamides et leurs derives modulant l'activite de l'endotheline
WO1998016520A1 (fr) * 1996-10-16 1998-04-23 American Cyanamid Company Preparation d'acides ortho-sulfonamido heteraryl-hydroxamiques et leur utilisation en tant qu'inhibiteurs des metalloproteinases matricielles et de tace
WO2001090092A1 (fr) * 2000-05-22 2001-11-29 Biovitrum Ab Inhibiteurs de 11-beta-hydroxy-steroide-deshydrogenase de type 1

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1240545A (en) * 1967-07-17 1971-07-28 Research Corp Silver-containing therapeutic agents
WO1996031492A1 (fr) * 1995-04-04 1996-10-10 Texas Biotechnology Corporation Thienyl-, furyl-, pyrrolyl- et biphenyl sulfonamides et leurs derives modulant l'activite de l'endotheline
WO1998016520A1 (fr) * 1996-10-16 1998-04-23 American Cyanamid Company Preparation d'acides ortho-sulfonamido heteraryl-hydroxamiques et leur utilisation en tant qu'inhibiteurs des metalloproteinases matricielles et de tace
WO2001090092A1 (fr) * 2000-05-22 2001-11-29 Biovitrum Ab Inhibiteurs de 11-beta-hydroxy-steroide-deshydrogenase de type 1

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
STOZOWSKA W. ET AL.: "Urinary silver and sulfathiazole levels in thermally injured guinea pigs during treatment with silver sulfathiazole cream", S.T.P. PHARMA SCIENCES, vol. 5, no. 6, 1995, pages 452 - 455, XP002981457 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7253196B2 (en) 2004-05-24 2007-08-07 Amgen, Inc. Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1
US7807700B2 (en) 2004-05-24 2010-10-05 Amgen Inc. Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1
US8686011B2 (en) 2004-05-24 2014-04-01 Amgen Inc. Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1
EP1791822A1 (fr) * 2004-08-05 2007-06-06 F.Hoffmann-La Roche Ag Aminothiazoles substitués n-acyle-2-
US7759339B2 (en) 2005-03-31 2010-07-20 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
WO2007025892A1 (fr) 2005-08-31 2007-03-08 F. Hoffmann-La Roche Ag Inhibiteur de la 11-bêta-hydroxystéroïde déhydrogénase-1 des diabètes de type 2-1
US7622492B2 (en) 2005-08-31 2009-11-24 Hoffmann-La Roche Inc. Pyrazolones as inhibitors of 11β-hydroxysteroid dehydrogenase
US8541592B2 (en) 2005-11-22 2013-09-24 Amgen Inc. Inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1
EP3235813A1 (fr) 2016-04-19 2017-10-25 Cidqo 2012, S.L. Dérivés aza-tétra-cycliques
WO2017182464A1 (fr) 2016-04-19 2017-10-26 Cidqo 2012, S.L. Nouveaux dérivés d'aza-tétracyclo

Also Published As

Publication number Publication date
SE0301885D0 (sv) 2003-06-25

Similar Documents

Publication Publication Date Title
EP1638553A1 (fr) Nouvelle utilisation i
WO2004112782A1 (fr) Utilisation v
WO2004113310A1 (fr) Utilisation d'un inhibiteur de compose de type 1 11-b-hydroxysteroide deshydrogenase type 1 destine a faciliter la cicatrisation d'une plaie
WO2004112779A1 (fr) Nouvelle utilisation vii
AU729243B2 (en) Troglitazone compounds for treating climacteric
CN100406006C (zh) 皮肤色素沉着的治疗剂
ZA200105823B (en) p53 inhibitors and therapeutic use of the same.
CA2687957A1 (fr) Produit pharmaceutique contenant un agoniste de ppar.delta.
WO2008063842A2 (fr) Méthodes de traitement de la douleur neuroapathique au moyen d'agonistes de ppar-gamma
EP0984780A1 (fr) Utilisation de derives de thiazolidinedione dans le traitement du syndrome des ovaires polykystiques ou du diabete gestationnel
KR20030016218A (ko) 티아졸, 이미다졸 및 옥사졸 화합물, 및 단백질 노화와관련된 장애의 치료
WO1999059586A1 (fr) Derives de thiazolidine et d'oxazolidine pour le traitement d'infarctus du myocarde aigus et pour l'inhibition de l'apoptose des cardiomyocytes
WO2004112783A1 (fr) Utilisation iv
JPWO2009051223A1 (ja) 白内障処置のための医薬組成物
WO2004112781A1 (fr) Nouvelle utilisation ii
BG65847B1 (bg) Приложение на производни на бигуанидина за получаване на лекарствено средство с цикатризиращ ефект
AU708315B2 (en) Treatment and prophylaxis of pancreatitis
WO2004112785A1 (fr) Nouvelle utilisation iii
AU731690B2 (en) Use of 5-(4-(2-(N-methyl-N-(2-pyridyl)amino)-ethoxy)benzyl) 2,4-thiazolidinedione in the treatment of polycystic ovary syndrome and gestational diabetes
KR20220035156A (ko) 베리누라드를 포함하는 과량 방출 저항성 약제학적 조성물
CA2417883A1 (fr) Composition pharmaceutique comprenant de la metformine et un derive de type 5-phenoxyalkyle-2,4-thiazolidinedione
JPH11510508A (ja) インシュリン非依存性真性糖尿病患者に投与される外来インシュリンの量を減らす方法
WO1997018811A1 (fr) Procede de traitement de dystrophie myotonique
US20040147430A1 (en) Use of antidiabetics for making a medicine with cicatrizing effect
RU2167656C2 (ru) Применение инсулинового сенсибилизатора для лечения и профилактики панкреатита

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
122 Ep: pct application non-entry in european phase